Kidney Cancer PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting kidney cancer. PDX models are known to be the most predictive preclinical model and provide an accurate approach to evaluating an agent’s efficacy prior to entering the clinic. The CrownBio kidney cancer PDX collection consists of several models, including models from both North American and Asian descent. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODELCANCER TYPESUBTYPE models per page
KI2367Kidney CancerRCCVIEW MODEL
KI2368Kidney CancerRCCVIEW MODEL
KI2389Kidney CancerCCRCCVIEW MODEL
KI2407Kidney CancerRCCVIEW MODEL
KI2432Kidney CancerNAVIEW MODEL
KI2552Kidney CancerNAVIEW MODEL